89 completed, 15 unknown, 10 recruiting, 6 terminated. 33 Not applicable, 25 Phase 2, 20 Phase 3, 20 Phase 4, 17 Phase 1.
Follow Capsaicin: new trials by email Literature Review of Capsaicin trials Research Report on Capsaicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Marsili Syndrome as a Gateway to Novel Analgesic Targets Histamine, Cowhage (Mucuna Pruriens), Capsaicin 8% Patch - Marsili Syndrome | Not applicable | Not yet recruiting | Aalborg University | 4 | 2026-08-01 | 2026-08-10 |
| The Role of TRP Channels in DPN Cinnamaldehyde, Allyl isothiocyanate (AITC), Capsaicin - Physiological Responses | Recruiting | Universitaire Ziekenhuizen KU Leuven | 20 | 2025-10-08 | 2025-11-19 | |
| Topographical Distribution of Itch and Pain Receptors Histamine, Cowhage, Capsaicin 8% Patch - Pain, Itch | Not applicable | Recruiting | Aalborg University | 30 | 2025-09-17 | 2025-10-01 |
| Topical Capsaicin Versus Diclofenac for Chronic Temporomandibular Joint-Related Pain Capsaicin Topical Cream, Diclofenac 1% Topical - Temporomandibular Disorders (TMD), Temporomandibular Pain | Not applicable | Completed | Istanbul University | 50 | 2025-08-28 | 2026-07-01 |
| Pain and Split-belt Motor Learning in Older Adults Capsaicin 0.1% cream combined with a heat pack and applied to the lower leg - Aging, Older Adults | Not applicable | Recruiting | University of Delaware | 34 | 2025-08-26 | 2025-12-04 |
| Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome Capsaicin 8% Patch, Serratus Plane Block, Botulinum Toxin A - Post-Mastectomy Neuropathic Pain Syndrome | Phase 2 | Withdrawn | Centre Oscar Lambret | 2025-06-10 | 2026-10-06 | |
| Peripheral KV7 Activation for Pain Relief Capsaicin only (7.6 ng), Capsaicin + Flupirtine 0.5 µg, Capsaicin + Flupirtine 1.2 µg - Pain | Early Phase 1 | Completed | Stefan Heber | 32 | 2025-05-08 | 2025-06-10 |
| Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy Capsaicin 8% - Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy | Active not recruiting | Averitas Pharma, Inc. | 144 | 2025-03-14 | 2026-07-13 | |
| Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy Qutenza® 8% Capsaicin Topical System - Lower Back Pain, Lumbosacral Radiculopathy | Enrolling by invitation | Medical University of South Carolina | 50 | 2025-03-13 | 2026-03-20 | |
| Capsaicin in Digital Osteoarthritis Versus Control Capsaicin 179 Mg Cutaneous Patch, Capsaicine low dose 0.04 % - Osteoarthritis Hand, Neuropathic Pain | Phase 4 | Recruiting | University Hospital, Clermont-Ferrand | 120 | 2025-03-07 | 2025-03-13 |
| Acute Effect of Capsimax on Resistance Exercise Performance, Muscle Oxygenation, Nitric Oxide Release, Resting Energy Expenditure and Reaction Time A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids - None Volunteer | Not applicable | Unknown | Hofstra University | 40 | 2024-10-01 | 2024-09-25 |
| Transient Receptor Potential Channels TRPM8 Agonist, TRPV1 Agonist, TRPV4 Agonist - Aging | Early Phase 1 | Enrolling by invitation | Penn State University | 45 | 2024-07-17 | 2026-07-27 |
| Session-Order Sensitivity of TS and OA in a Capsaicin Crossover Model Topical 0.075% capsaicin cream (Zostrix), Topical vehicle lotion (Lubriderm) - Hyperalgesia, Pain Perception | Not applicable | Completed | University of Guelph | 16 | 2024-05-01 | 2026-06-04 |
| Chemotherapy Induced Peripheral Neuropathy by Taxanes and Capsaicin 8%. Capsaicin 8% Patch, antidepressants (tricyclics and serotonin reuptake inhibitor SRIs), antiepiletics, lidocaine patches, and neurostimulation - Patients With Taxane-induced Chronic Neuropathic Pain | Not applicable | Recruiting | Hospital Ambroise Paré Paris | 50 | 2024-03-12 | 2026-05-22 |
| Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children Capsaicin 8% patch, Hydrocolloid dressing - Neuropathic Pain, Chronic Pain | Phase 3 | Recruiting | University Hospital, Brest | 46 | 2024-03-05 | 2026-06-15 |
| Is Nociceptive Processing Evoked by Heat Homeostatically Regulated: A Contact-heat Evoked Potentials Study Homeostatic Plasticity, Topical alone (Capsaicin 8% Patch), Placebo Patch - Healthy | Not applicable | Completed | Aalborg University | 18 | 2023-11-21 | 2024-05-16 |
| Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia Capsaicin - Coccyx Disorder | Recruiting | Nantes University Hospital | 106 | 2023-11-08 | 2026-06-23 | |
| Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. Capsaicin 179 Mg Cutaneous Patch, Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2) - Coccyx Disorder, Neuropathic Pain | Phase 3 | Recruiting | Nantes University Hospital | 188 | 2023-11-08 | 2026-10-09 |
| Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy Capsaicin, Duloxetine - Chemotherapy-induced Peripheral Neuropathy | Phase 3 | Recruiting | Institut Cancerologie de l'Ouest | 274 | 2023-10-20 | 2026-03-31 |
| A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420) Allyl Isothiocyanate (AITC), Capsaicin, Vehicle for AITC - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 12 | 2023-09-25 | 2025-02-05 |
Showing 20 of 131. Sign in to see all of them.
Pain (24) · Neuralgia (18) · Osteoarthritis, Knee (7) · Cough (6) · Neuralgia, Postherpetic (5) · Osteoarthritis (5) · Peripheral Nervous System Diseases (5) · Acute Pain (4) · Agnosia (4) · Deglutition Disorders (4) · Diabetic Neuropathies (4) · Pruritus (4) · Stroke (4) · Chronic Pain (3) · Hyperalgesia (3)
Aalborg University (8) · University of Florida (8) · NeurogesX (5) · Universitaire Ziekenhuizen KU Leuven (5) · Astellas Pharma Inc (4) · Centrexion Therapeutics (4) · Maastricht University Medical Center (3) · National Institute of Dental and Craniofacial Research (NIDCR) (3) · Wake Forest University (3) · Astellas Pharma Europe Ltd. (2) · Averitas Pharma, Inc. (2) · Bassett Healthcare (2) · Boehringer Ingelheim (2) · Copenhagen University Hospital, Rigshospitalet (2) · Hospital de Mataró (2)
United States (48) · France (17) · Denmark (13) · United Kingdom (12) · Belgium (11) · Netherlands (7) · Spain (7) · Austria (5) · Canada (5) · Czechia (5) · Italy (4) · Poland (4) · Germany (3) · Greece (3) · Russia (3)
Jeffrey Tobias, MD (3) · Dhananjai Menzies, MD (2) · Emma L Aitken, MBChB (2) · Gil Yosipovitch, MD (2) · Randall M. Stevens, MD (2) · Ad Masclee, MD PhD (1) · Adam M Gonzalez, PhD (1) · Ahmar U Zaidi, MD (1) · Alexander K Glaros, MD (1) · Alexandra E. Brandimore, M.A. (1) · Alexandra E. Brandimore, M.A. CCC/SLP (1) · Amber U Luong, MD, PhD (1)
PMID 11927685, PMID 12122152, PMID 12237259, PMID 12793996, PMID 15153776, PMID 15498811, PMID 15563538, PMID 18977178, PMID 20400377, PMID 21087403, PMID 21441148, PMID 22067661, PMID 22182397, PMID 23351618, PMID 24062200, PMID 24326980, PMID 25290151, PMID 26718419, PMID 27130637, PMID 27398981, PMID 27746370, PMID 27919222, PMID 28431564, PMID 29024230, PMID 30956054, PMID 32221866, PMID 32439432, PMID 33197270, PMID 33308274, PMID 33799960, PMID 33966493, PMID 34044838, PMID 34215800, PMID 34554688, PMID 34799534, PMID 35351835, PMID 35460440, PMID 36142680, PMID 36729473, PMID 37089721, PMID 38905580, PMID 40050054, PMID 42548348, PMID 9291902
2009 (2), 2015 (1), 2016 (1), 2017 (1), R01AG071585 (1), R01DK049524 (1), R01HD091658 (1)